Scholarlink

Background <p>The treatment summary (TS) remains underused in head and neck cancer (HNC). We determine if receiving a personalized TS following a definitive HNC treatment improves patient recall of treatment details.</p> Method <p>A history questionnaire was administered to assess patient accuracy in reporting diagnosis and treatment-related details at baseline (pre-TS) and 1-month follow-up (post-TS). Statistical significance of accuracy changes was assessed using McNemar’s chi squared test.</p> Results <p>One hundred participants were enrolled between January and December 2022. Ninety-one completed all surveys. Significant improvement in correct responses was noted for questions regarding cancer diagnosis type (94.5% post-TS, 78.0% pre-TS, <i>p</i> = 0.002), cancer diagnosis date (75.8% post-TS, 40.7% pre-TS, <i>p</i> &lt; 0.001), T-stage (82.4% post-TS, 28.6% pre-TS, <i>p</i> &lt; 0.001), and lymph node status (91.2% post-TS, 63.7% pre-TS, <i>p</i> &lt; 0.001).</p> Conclusion <p>TS may improve HNC survivors’ recall about their diagnosis and treatment in the short term. Patients view TS as beneficial to their survivorship care plans.</p> Implications for Cancer Survivors <p>TS in survivorship care plans are understudied in HNC patients. This investigation will serve as a meaningful contribution to the literature, promote additional investigation, and encourage improvement of informative resources available to HNC survivors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment summaries for head and neck cancer survivors: a pilot study to improving patient recall and survivorship care plans

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月4日

查看全文
  • Shreyas G. Krishnapura,
  • Aaron X. Lee,
  • Tatsuki Koyama,
  • James L. Netterville,
  • Kyle Mannion,
  • Alexander J. Langerman,
  • Robert Sinard,
  • Sarah L. Rohde,
  • Michael C. Topf

摘要

Background

The treatment summary (TS) remains underused in head and neck cancer (HNC). We determine if receiving a personalized TS following a definitive HNC treatment improves patient recall of treatment details.

Method

A history questionnaire was administered to assess patient accuracy in reporting diagnosis and treatment-related details at baseline (pre-TS) and 1-month follow-up (post-TS). Statistical significance of accuracy changes was assessed using McNemar’s chi squared test.

Results

One hundred participants were enrolled between January and December 2022. Ninety-one completed all surveys. Significant improvement in correct responses was noted for questions regarding cancer diagnosis type (94.5% post-TS, 78.0% pre-TS, p = 0.002), cancer diagnosis date (75.8% post-TS, 40.7% pre-TS, p < 0.001), T-stage (82.4% post-TS, 28.6% pre-TS, p < 0.001), and lymph node status (91.2% post-TS, 63.7% pre-TS, p < 0.001).

Conclusion

TS may improve HNC survivors’ recall about their diagnosis and treatment in the short term. Patients view TS as beneficial to their survivorship care plans.

Implications for Cancer Survivors

TS in survivorship care plans are understudied in HNC patients. This investigation will serve as a meaningful contribution to the literature, promote additional investigation, and encourage improvement of informative resources available to HNC survivors.